making near vision clear again

For people with presbyopia

Eliminating
the need for reading glasses

For people with presbyopia

Empowering patients with unparalleled comfort and control of their near vision 

what is presbyopia

Presbyopia, the inability to focus on close objects, is common after age 40 and affects more then 1.8 billion people worldwide. Current treatment options are either cumbersome or invasive, presenting a significant unmet need for quality of life improvement for people with presbyopia.

our solution

Our eye drop to treat presbyopia is in clinical development. Our winning combination of existing and well-known components targets the right balance of efficacy, safety and comfort.

company updates

October 28 2020

Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

September 10 2020

Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia

May 11 2020

Chief executive officer Elad Kedar spoke with the OIS Podcast on his strategy for success in completing a Phase 2b clincal study and how Orasis is now preparing to move into Phase 3 with our product candidate CSF-1. Chairman Jeffry Weinhuff also offers insights into Visionary Ventures’ investment decisions. Listen to the full podcast here.

Jan 28 2020

Chief executive officer, Elad Kedar, spoke with the Bio Report podcast on the potential of CSF-1 to treat presbyopia or age-related farsightedness and the eye drop’s recent positive Phase 2b study results. Listen to the full podcast here.

Nov 14 2019

Following the positive results from our Phase 2b U.S. clinical trial of CSF-1, Orasis CEO Elad Kedar spoke with Healio Ocular Surgery News about the eye drop and its potential as a meaningful treatment for people with presbyopia. Watch the full interview

May 29 2019

Orasis CEO Elad Kedar was interviewed by Ophthalmology Innovation Summit (OIS) TV about our corrective eye drop for the treatment of presbyopia and progress in our Phase 2b clinical study

Apr 8 2019

CEO Elad Kedar Discusses Our Ongoing Phase 2b Clinical Study of CSF-1 and the Eye Drop’s Treatment Effect with Healio

Mar 27 2019

Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

Oct 10 2019

Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

May 29 2019

Orasis CEO Elad Kedar was interviewed by Ophthalmology Innovation Summit (OIS) TV about our corrective eye drop for the treatment of presbyopia and progress in our Phase 2b clinical study

Apr 8 2019

CEO Elad Kedar Discusses Our Ongoing Phase 2b Clinical Study of CSF-1 and the Eye Drop’s Treatment Effect with Healio

Mar 27 2019

Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia